Current Status of Supplemental Screening in Dense Breasts

Wendie A. Berg, Magee-Womens Hospital of University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, and the University of Pittsburgh School of Medicine, Pittsburgh, PA

See accompanying article doi:10.1200/JCO.2015.65.8674

Currently, 24 American states have laws requiring that women receive some level of notification about breast density with their mammography results.1 Dense breast tissue can hide cancer on mammography, especially when the cancer lacks calcifications, resulting in delayed diagnosis and worse outcomes. Moreover, dense breast tissue is an independent risk factor for developing breast cancer. Particularly in dense (heterogeneously dense or extremely dense) breasts, a negative result on mammography does not reliably exclude the presence of cancer. Advocates pushed for legislation requiring that notification of breast density be given with mammography results so that women with dense breasts would be aware of the implications, and could pursue supplemental screening beyond mammography. The most widely available supplemental screening options for women with dense breasts are ultrasound (US) and tomosynthesis (three-dimensional [3D] mammography), but there has been a lack of information to guide the decision to have one or the other versus both. Preliminary results from the Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts (ASTOUND) trial, an important study of adjunct screening with US and tomosynthesis (3D mammography) in women with dense breasts, are presented in the accompanying article in Journal of Clinical Oncology.2

Even with modern treatments for breast cancer, stage at diagnosis, and especially node status, remain the most important prognostic factors.3 Across 11 randomized trials of mammography, only those that reduced the rate of advanced breast cancer (and increased detection of node-negative invasive cancer) produced breast-cancer mortality reduction.4,5 In women with dense breasts, invasive cancers may be masked and missed on mammography; as a result, there is an excess of late-stage disease (stages II and III).6 In women with extremely dense breasts, cancers are nearly 18 times more likely to be found because of clinical symptoms soon after a normal screening mammogram than in women with fatty breasts.7 Such interval cancers (ie, diagnosed before the next routine screening examination) tend to be larger, more aggressive, and have worse prognoses than those found on screening. Thus, another measure of screening effectiveness is a low interval cancer rate (typically less than one per 1,000 women screened per year).

Results from screening US have been reported in more than 200,000 women. The vast majority of US studies have examined its addition to mammography for women with dense breasts, and the vast majority of cancers seen only on US prospectively are not evident on mammography, even in retrospect. In a review of 335 cancers seen only on screening US, Bae et al6 reported that 263 (78%) were obscured by dense tissue on mammography, 63 (19%) were interpretive errors on mammography, and nine (3%) were not included mammographically because of difficult location or positioning. When performed by physicians, US produces consistent increased detection of an average of four cancers per 1,000 women screened.9-15 More than 85% of cancers detected only on screening US are invasive and node negative.16 Technologists can also be trained to perform whole-breast handheld screening US. On video review of results from training courses in Japan, 415 technologists showed significantly better performance in lesion detection than 422 physicians (85.9% v 84.0%, respectively; P = .037) and higher specificity on still images (86.6% v 85.1%, respectively; P = .026), with indistinguishable performance on other tasks.17 In recently published results from the Japan Strategic Anti-Cancer Randomized Trial (J-START), there was a reduction in interval cancers (0.05% v 0.10%; P = .034) among 32,105 women receiving supplemental US compared with 32,812 women in the control group receiving only mammography; notably, only 57.7% of women in J-START had dense breasts, although results by breast density were not detailed.18 Compared with results from physician-performed US, studies of technologist-performed screening US have shown slightly lower added cancer detection, averaging 2.5 per 1,000 women in the first year.19 Several different approaches to automated whole-breast US have been studied. One method uses an automated arm with standard handheld equipment and, in a multicenter experience, showed detection of an additional 3.6 cancers per 1,000 women screened after mammography.20 Another approach uses a transducer with a wide footprint (typically 15 cm) and produced a supplemental yield of 1.9 per 1,000 women in a prospective multicenter experience, although 13% of women required recall for additional targeted US to complete initial screening.21 Results are expected to improve with incidence screening.

There are several barriers to implementing screening US in practice. One of these has been high rates of false positives due to US. Importantly, in preliminary results from the ASTOUND trial,2 false-positive recalls (2.0%) and biopsies (0.7%) were
acceptable low. These low rates likely reflect that most of the US screens in ASTOUND were incident screens (with prior examinations available); further, recommendations for short-interval follow up (Breast Imaging-Reporting and Data System density categories three) were not considered test positive. Results from incidence screening in years 2 and 3 in ACRIN (American College of Radiology Imaging Network) 6666 showed far fewer false positives than in year 1. In Connecticut, where reporting of the limitations of mammography in dense breasts directly to the patient has been mandated since 2009, and where supplemental screening with US or magnetic resonance imaging (MRI) is required to be covered by insurance, many practices have implemented screening US for women with dense breasts. Comparing year 5 screening US results to those in year 1 at a practice affiliated with Yale, the recall rate dropped from 25% to 6% (P < .001), the biopsy rate from 5% to 1% (P < .001), and the positive predictive value of biopsies increased to 25% from 6.5% (P < .001), while maintaining similar cancer detection rates of 2.6 per 1,000 in year 5 versus 3.2 per 1,000 in year 1.

Another barrier to implementing screening US is manpower. For handheld US, training of investigators and use of a consistent scanning protocol produced excellent results in the ACRIN 6666 trial, but it is impractical to expect radiologist physicians to perform screening US in the United States. Although technologists are encouraged to use the same scanning and documentation protocol, standardized training is not generally available for technologists in the United States. With automated approaches, thousands of images are generated and interpretation times averaged 9 minutes for a bilateral examination in one early study, compared with less than 0.5 minute for a handheld examination with standard documentation. For the patient, there is the additional barrier of out-of-pocket costs due to deductible and copays with most insurance in most states. Medicare reimbursement currently averages $165 for whole-breast US of both breasts, regardless of whether this is performed by a physician or a technologist, or is automated.

Digital breast tomosynthesis, which is essentially 3D mammography, is much easier to implement. Once the equipment is in place, a technologist positions the patient exactly the same way as for standard mammography and simply pushes a button to obtain tomosynthesis instead of (or in combination with) a standard digital mammogram. Although, compared with standard mammography, there are many more images to review (usually one for each millimeter of breast thickness in each view), the images are quite familiar to radiologists trained in mammographic interpretation. Compared with two-dimensional (2D) mammography alone, adding 3D mammography increases cancer detection across all breast densities, with an average added cancer detection yield of 1.3 per 1,000 screens in a large retrospective analysis. When performed with 2D mammography, 3D mammography reduces false-positive recalls because areas of overlapping normal tissue are easily recognized.

The ASTOUND trial only considered women with negative mammograms and found a false-positive recall rate of 53 per 3,207 (1.7%) and a false-positive biopsy rate of 22 per 3,207 (0.7%) due to 3D mammography on the prevalent (first) screening round.

When 3D mammography is added to standard digital mammography, the radiation dose is a little more than doubled. Synthetic 2D reconstructions from the projection images obtained for tomosynthesis can replace standard 2D mammography, so that the radiation dose for 2D plus 3D mammography is comparable to 2D alone. However, radiologists have been slow to adopt this approach to date because small masses can be difficult to see on synthetic 2D images, resulting in reduced diagnostic confidence. Although the added cancer detection yield of tomosynthesis is modest, the concomitant reduction in false positives in prior studies adding 3D to 2D mammography, with a net increase in accuracy, make this method attractive. Insurance coverage for tomosynthesis is highly variable at this time. However, the state of Pennsylvania recently determined that mammography is mammography and the insurance commissioner decreed that screening 3D mammography falls under the same mandatory full coverage as 2D mammography. At this time, national screening coverage only includes 2D mammography under the Affordable Care Act. Medicare reimbursement averages $57 for tomosynthesis.

ASTOUND is the first published prospective trial to directly compare US and tomosynthesis for adjunct screening after standard mammography in women with dense breasts. The added cancer detection yield of 7.1 per 1,000 screens (95% CI, 4.2 to 10) for US was significantly higher than that from tomosynthesis at 4.0 per 1,000 screens (95% CI, 1.8 to 6.2; P = .006), with only one cancer seen only on tomosynthesis. The difference in yields in favor of US is consistent with results of prior trials of each modality separately, although the absolute yields are higher than in prior studies. Preliminary results from the University of Pennsylvania suggest that the cancer detection benefit from tomosynthesis is maintained each year, although further study is needed; this has been shown for US. The low interval cancer rate of 0.82 per 1,000 screens in the first year of the multicenter Italian trial of tomosynthesis is encouraging. However, this was across all breast densities. Further evaluation is warranted and is a proposed end point of the Tomosynthesis-Mammography Imaging Screening Trial (T-MIST).

Because the primary goal of screening is detection of early breast cancer, US would seem the clear choice compared with tomosynthesis. Given comparable false-positive rates in ASTOUND, the estimated cost per cancer detected would be similar or more favorable for US than tomosynthesis. US equipment is becoming much less expensive, requires no ionizing radiation, and it is easy to guide needle biopsy of lesions seen only on US. A recent analysis from ACRIN 6666 showed comparable cancer detection for US alone as for mammography alone, with more of the cancers seen on US being invasive and node negative. US was complementary to mammography and should be seen as a supplement to mammography where both are available. On the basis of the results from ASTOUND, tomosynthesis still misses a substantial number of invasive cancers in women with dense breasts: supplemental US after tomosynthesis would still be reasonable, although further study is warranted.

For high-risk women of any breast density, supplemental screening with annual MRI has been proven to reduce late-stage disease and to produce increased metastasis-free survival. In 2016, the American Cancer Society plans to update its guideline for screening women at high risk, and will include breast density and other risk factors in its systematic evidence review. The American Cancer Society’s recent guideline for average-risk
women recommends that women start screening by age 45 years, and by age 40 years if the woman is willing to accept the risk of false positives. Preliminary results in average-risk women indicate that MRI has a much higher cancer detection rate than US or tomosynthesis of greater than 22 per 1,000 in year 1 and 7.5 per 1,000 in subsequent years. This is even after undergoing digital mammography and physician-performed screening US, with 93% of cancers seen on MRI being node negative, across all breast densities. Insurance reimbursement for screening MRI typically exceeds $1,000, which has prompted interest in a lower-cost alternative that uses an abbreviated protocol. In a pioneering study of fast MRI from Kuhl et al, all 11 cancers were detected by both fast and standard MRI. The false-positive rate for fast MRI was substantial but insignificantly higher than for standard MRI among 595 women without cancer (87 [14.6%] v 70 [11.8%]), P = .17 if short-interval follow-up (Breast Imaging-Reporting and Data System density categories three) cases were included among false positives. An ACRIN-ECOG (Eastern Cooperative Oncology Group) multicenter trial that will prospectively evaluate abbreviated MRI is eagerly awaited.

In summary, preliminary results from ASTOUND are extremely important in helping to inform personalized screening choices for women with dense breasts. Guidelines on these issues are planned, but often limit recommendations to those based on evidence from randomized trials with mortality as an end point. Our knowledge of the natural history of breast cancer and results from randomized trials of mammography should inform guidelines for supplemental screening. Methods that improve detection of node-negative invasive cancer should benefit women; a reduction in interval cancers has been shown for screening US, and a reduction in late-stage disease and improved metastasis-free survival has been shown for MRI. For tomosynthesis, the benefits are likely more modest. For women with dense breasts given the choice of US or tomosynthesis, US shows more cancers. Further validation of these results is critically needed, as is longer-term follow up to compare incidence screening results for tomosynthesis and US.

AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the author are available with this article at www.jco.org.

REFERENCES


DOI: 10.1200/JCO.2015.65.8674; published online ahead of print at www.jco.org on March 9, 2016.
AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Current Status of Supplemental Screening in Dense Breasts

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Wendie A. Berg
Consulting or Advisory Role: SuperSonic Imagine
Acknowledgment

W.A.B. supported by Grant R01CA187593 from the National Institutes of Health, National Cancer Institute; UH2 EB0198889 from the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering.